Loading...
Market
What will be the percentage increase of AbbVie's 2025 dividend?
3
Resolution / Starting Odds
Less than 5% • 25%
5% to 6% • 25%
6% to 7% • 25%
More than 7% • 25%
AbbVie's official dividend announcement for 2025
Story
AbbVie Q3 Adjusted EPS $3.00 Beats Estimates; Revenue $14.46B; Skyrizi Sales Up 51%, Raises FY2024 Guidance
Oct 30, 2024, 11:42 AM
AbbVie Inc. reported its third-quarter 2024 financial results, surpassing analysts' expectations. The company's adjusted earnings per share (EPS) increased 1.7% year-over-year to $3.00, exceeding the estimated $2.91, despite an unfavorable impact of $0.04 per share related to acquired in-process research and development (IPR&D) and milestone expenses. On a GAAP basis, diluted EPS was $0.88, a decrease of 12.0%. Revenue rose by 3.8% to $14.46 billion, beating the consensus estimate of $14.28 billion. Strong sales of Skyrizi and Rinvoq offset the decline in Humira revenue. Skyrizi net revenue surged 51% to $3.21 billion, higher than the expected $3.0 billion. Global Humira net revenue declined by 37.2% to $2.22 billion, slightly below the estimated $2.36 billion. AbbVie raised its full-year 2024 adjusted EPS guidance to a range of $10.90 to $10.94, up from the previous range of $10.67 to $10.87, reflecting confidence in its growth prospects. Additionally, the company announced a 5.8% increase in its 2025 dividend.
View original story
Similar markets
Less than 5% • 25%
5% to 5.5% • 25%
5.5% to 6% • 25%
Greater than 6% • 25%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
ABBV up, GMAB up • 25%
ABBV up, GMAB down • 25%
ABBV down, GMAB up • 25%
ABBV down, GMAB down • 25%
No growth • 25%
1% to 3% • 25%
3% to 5% • 25%
Above 5% • 25%
Significant growth (>10%) • 25%
Moderate growth (5-10%) • 25%
Minimal growth (<5%) • 25%
No growth or decline • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 60 cents • 25%
60 cents • 25%
61 to 65 cents • 25%
More than 65 cents • 25%
Below 9.5% • 25%
9.5% - 9.6% • 25%
9.7% - 9.8% • 25%
9.9% - 10.0% • 25%
$0.59 • 25%
$0.65 • 25%
$0.70 • 25%
Above $0.70 • 25%
Increased • 25%
Decreased • 25%
Unchanged • 25%
Other • 25%